HomeDiscoveryCongressi ed eventiCongressi ed eventi 2014

Congressi ed eventi 2014

2014

Novembre 18-21
26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Barcelona, Spain
Web link
Abstract
Identification and characterization of selective MELK kinase inhibitors
Abstract
N-Myc amplification sensitizes tumor cells to inhibition by Danusertib, an Aurora kinase inhibitor

Ottobre 26-29
5th Annual World ADC Summit
San Diego, CA
Web link
Abstract
NMS-P945 a new drug-linker highly suited to generation of novel antibody drug conjugates (ADCs)

Settembre 26-30
ESMO 2014
Madrid, Spain
Web link
Poster 448PD. Presentation time: Sunday, Settembre 28, 1:00 - 2:00 PM, Location: Alicante Conference Area
RXDX-101, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations

Settembre 7-11
XXIII National Meeting on Medicinal Chemistry
Lisbone, Portugal
Web link

Giugno 19-21
26th Pezcoller Symposium: "Cancers driven by hormones"
Trento, Italy
Web link

Giugno 11-13
8th MS Pharmaday
Sansepolcro, Italy
Web link

Giugno 9-10
VIII Meeting Nuove Prospettive in Chimica Farmaceutica
Parma, Italia
Web link
Oral presentation
Evoluzione delle terapie antitumorali da un punto di vista chimico-medicinale
D. Donati

Maggio 30-Giugno 3
ASCO Annual Meeting 2014
Chicago, USA
Web link
Abstract 2502. Presentation time: Saturday Maggio 31, 1:15 - 4:15 PM Location: E Hall D2
Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations
Abstract 7526. Presentation time: Sunday Giugno 1, 8:00 - 11:00 AM Location 1: S405 and 11:30 AM to 12:45 PM Location 2: S406
A phase II study of milciclib (PHA-848125AC) in patients (pts) with thymic carcinoma (TC)

Maggio 26-27
1st IMaSS Network Conference, Scientific Networks for Innovation
Rome, Italy

Aprile 5-9
AACR 2014
San Diego, CA
Web link
Abstract 822/9. Presentation time: Sun, Apr 06, 1:00 - 5:00 PM
Thienoindoles, a novel class of DNA minor groove alkylating agents highly suited for the generation of novel antibody drug conjugates (ADCs)
Abstract 4539/25. Presentation time: Tue, Apr 08, 1:00 - 5:00 PM
NMS-P862, a novel orally available selective small molecule Cdc7 inhibitor with antitumor efficacy in breast cancer